Molecular Partners AG (MOLN) - Net Assets

Latest as of September 2025: CHF95.53 Million CHF ≈ $120.77 Million USD

Based on the latest financial reports, Molecular Partners AG (MOLN) has net assets worth CHF95.53 Million CHF (≈ $120.77 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF112.15 Million ≈ $141.79 Million USD) and total liabilities (CHF16.62 Million ≈ $21.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Molecular Partners AG (MOLN) tangible net worth to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CHF95.53 Million
% of Total Assets	85.18%
Annual Growth Rate	10.27%
5-Year Change	32.1%
10-Year Change	-6.69%
Growth Volatility	75.28

Molecular Partners AG - Net Assets Trend (2013–2024)

This chart illustrates how Molecular Partners AG's net assets have evolved over time, based on quarterly financial data. See MOLN cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Molecular Partners AG (2013–2024)

The table below shows the annual net assets of Molecular Partners AG from 2013 to 2024. For live valuation and market cap data, see Molecular Partners AG market cap and net worth.

Year	Net Assets	Change
2024-12-31	CHF141.64 Million ≈ $179.07 Million	-19.72%
2023-12-31	CHF176.43 Million ≈ $223.05 Million	-24.98%
2022-12-31	CHF235.17 Million ≈ $297.31 Million	+119.19%
2021-12-31	CHF107.29 Million ≈ $135.64 Million	+0.06%
2020-12-31	CHF107.22 Million ≈ $135.56 Million	+98.05%
2019-12-31	CHF54.14 Million ≈ $68.45 Million	-40.96%
2018-12-31	CHF91.70 Million ≈ $115.94 Million	-21.44%
2017-12-31	CHF116.73 Million ≈ $147.58 Million	-14.04%
2016-12-31	CHF135.79 Million ≈ $171.68 Million	-10.54%
2015-12-31	CHF151.79 Million ≈ $191.91 Million	+2.23%
2014-12-31	CHF148.48 Million ≈ $187.72 Million	+207.31%
2013-12-31	CHF48.32 Million ≈ $61.08 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Molecular Partners AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 23224131800.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	CHF4.04 Million	2.85%
Other Components	CHF383.89 Million	271.04%
Total Equity	CHF141.64 Million	100.00%

Molecular Partners AG Competitors by Market Cap

The table below lists competitors of Molecular Partners AG ranked by their market capitalization.

Company	Market Cap
Hoteles City Express S.A.B. de C.V MX:HCITY	$145.94 Million
Syncom Formulations (India) Limited NSE:SYNCOMF	$145.98 Million
American Rare EARTHS Ltd AU:ARR	$145.98 Million
Cegedim S.A. PA:CGM	$145.99 Million
Tavia Acquisition Corp. Unit NASDAQ:TAVIU	$145.77 Million
Huangshan Tourism Development Co Ltd B SHG:900942	$145.64 Million
Mikro MSC Bhd KLSE:0112	$145.62 Million
Plenitude Bhd KLSE:5075	$145.60 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Molecular Partners AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 176,429,000 to 141,637,000, a change of -34,792,000 (-19.7%).
Net loss of 54,043,000 reduced equity.
Share repurchases of 17,382,000 reduced equity.
New share issuances of 17,342,000 increased equity.
Other factors increased equity by 19,291,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CHF-54.04 Million	-38.16%
Share Repurchases	CHF17.38 Million	-12.27%
Share Issuances	CHF17.34 Million	+12.24%
Other Changes	CHF19.29 Million	+13.62%
Total Change	CHF-	-19.72%

Book Value vs Market Value Analysis

This analysis compares Molecular Partners AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.76x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 1.27x to 0.76x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2013-12-31	CHF2.48	CHF3.15	x
2014-12-31	CHF9.71	CHF3.15	x
2015-12-31	CHF7.77	CHF3.15	x
2016-12-31	CHF6.65	CHF3.15	x
2017-12-31	CHF5.60	CHF3.15	x
2018-12-31	CHF4.33	CHF3.15	x
2019-12-31	CHF2.53	CHF3.15	x
2020-12-31	CHF4.29	CHF3.15	x
2021-12-31	CHF3.46	CHF3.15	x
2022-12-31	CHF7.07	CHF3.15	x
2023-12-31	CHF5.38	CHF3.15	x
2024-12-31	CHF4.16	CHF3.15	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Molecular Partners AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -38.16%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -1087.38%
• Asset Turnover: 0.03x
• Equity Multiplier: 1.12x
Recent ROE (-38.16%) is below the historical average (-22.58%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	14.78%	22.03%	0.29x	2.28x	CHF2.31 Million
2014	-1.54%	-8.57%	0.14x	1.31x	CHF-17.13 Million
2015	-0.10%	-0.51%	0.13x	1.45x	CHF-15.33 Million
2016	-13.71%	-80.78%	0.13x	1.36x	CHF-32.19 Million
2017	-21.79%	-127.05%	0.14x	1.24x	CHF-37.10 Million
2018	-40.39%	-357.66%	0.07x	1.69x	CHF-46.21 Million
2019	-67.03%	-178.03%	0.19x	1.94x	CHF-41.70 Million
2020	-58.54%	-671.70%	0.05x	1.75x	CHF-73.49 Million
2021	-59.45%	-683.65%	0.05x	1.61x	CHF-74.51 Million
2022	50.11%	62.17%	0.72x	1.12x	CHF94.34 Million
2023	-35.13%	-880.70%	0.04x	1.12x	CHF-79.63 Million
2024	-38.16%	-1087.38%	0.03x	1.12x	CHF-68.21 Million

Industry Comparison

This section compares Molecular Partners AG's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $310,217,525
Average return on equity (ROE) among peers: -38.18%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Molecular Partners AG (MOLN)	CHF95.53 Million	14.78%	0.17x	$145.86 Million
Addex Therapeutics Ltd (ADXN)	$16.93 Million	-91.05%	0.33x	$6.98 Million
Bachem Holding AG (BANB)	$365.36 Million	11.28%	0.36x	$5.20 Billion
BB Biotech AG (BION)	$3.29 Billion	-12.31%	0.11x	$2.48 Billion
Bioversys AG (BIOV)	$10.68 Million	-175.24%	2.27x	$161.41 Million
Basilea Pharmaceutica AG (BSLN)	$210.24 Million	51.16%	0.51x	$686.09 Million
Idorsia Ltd (IDIA)	$-1.21 Billion	0.00%	0.00x	$1.03 Billion
MINDMAZE THERAPEUTICS HOLDING SA (MMTX)	$38.34 Million	-25.84%	0.34x	$49.96 Million
Newron Pharmaceuticals SpA (NWRN)	$36.80 Million	-54.91%	0.64x	$297.11 Million
Relief Therapeutics Holding AG (RLF)	$36.66 Million	-46.69%	0.45x	$36.33 Million

About Molecular Partners AG

SW:MOLN Switzerland Biotechnology

Market Cap

$148.94 Million

CHF117.81 Million CHF

Market Cap Rank

#17843 Global

#181 in Switzerland

Share Price

CHF3.15

Change (1 day)

+3.96%

52-Week Range

CHF2.75 - CHF3.95

All Time High

CHF38.40